A lipid nanocomposite modified with apolipoprotein A-I, its mimetic peptide 4F, and angioendothelin-2 crosses the BBB, targets microglia, eliminates amyloid-β, and inhibits tau phosphorylation, which significantly improves AD pathology (Han et al., 2022). This evidence concerns the gene MAPT and Alzheimer disease.